Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Espinel-Ingroff A, et al. Among authors: hockey h. J Antimicrob Chemother. 2008 Mar;61(3):616-20. doi: 10.1093/jac/dkm518. Epub 2008 Jan 25. J Antimicrob Chemother. 2008. PMID: 18222957 Clinical Trial.
METHODS: MICs were measured using CLSI M38-A 48 h microdilution methodology. RESULTS: Moulds from 29 genera and 38 species were isolated from 18 countries. ...
METHODS: MICs were measured using CLSI M38-A 48 h microdilution methodology. RESULTS: Moulds from 29 genera and 38 species were isola …
Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.
Troke PF, Hockey HP, Hope WW. Troke PF, et al. Among authors: hockey hp. Antimicrob Agents Chemother. 2011 Oct;55(10):4782-8. doi: 10.1128/AAC.01083-10. Epub 2011 Jul 18. Antimicrob Agents Chemother. 2011. PMID: 21768513 Free PMC article.
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P. Johnson E, et al. Among authors: hockey h. Int J Antimicrob Agents. 2008 Dec;32(6):511-4. doi: 10.1016/j.ijantimicag.2008.05.023. Epub 2008 Sep 13. Int J Antimicrob Agents. 2008. PMID: 18790613
Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab.
Jordan SC, Kucher K, Bagger M, Hockey HU, Wagner K, Ammerman N, Vo A. Jordan SC, et al. Among authors: hockey hu. Am J Transplant. 2020 Apr 16. doi: 10.1111/ajt.15922. Online ahead of print. Am J Transplant. 2020. PMID: 32301258
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
Bruin G, Hockey HP, La Stella P, Sigurgeirsson B, Fu R, Patekar M, Charef P, Woessner R, Boutouyrie-Dumont B. Bruin G, et al. Among authors: hockey hp. Br J Clin Pharmacol. 2020 Feb;86(2):338-351. doi: 10.1111/bcp.14155. Epub 2020 Jan 7. Br J Clin Pharmacol. 2020. PMID: 31658377 Free PMC article.
TORC1 inhibition enhances immune function and reduces infections in the elderly.
Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, Watkins M, Shavlakadze T, Zhou W, Quinn D, Glass DJ, Klickstein LB. Mannick JB, et al. Among authors: hockey hp. Sci Transl Med. 2018 Jul 11;10(449):eaaq1564. doi: 10.1126/scitranslmed.aaq1564. Sci Transl Med. 2018. PMID: 29997249 Clinical Trial.
Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure.
Storgaard LH, Hockey HU, Laursen BS, Weinreich UM. Storgaard LH, et al. Among authors: hockey hu. Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1195-1205. doi: 10.2147/COPD.S159666. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29713153 Free PMC article. Clinical Trial.
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B. Trenkwalder C, et al. Among authors: hockey hu. Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15. Mov Disord. 2016. PMID: 26990766 Clinical Trial.
Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab.
Grosskreutz CL, Hockey HU, Serra D, Dryja TP. Grosskreutz CL, et al. Among authors: hockey hu. Cornea. 2015 Dec;34(12):1551-6. doi: 10.1097/ICO.0000000000000627. Cornea. 2015. PMID: 26418434 Free PMC article. Clinical Trial.
17 results
Jump to page
Feedback